Universe Pharmaceuticals INC — FY2023 Form 20-F
Reporting period: Fiscal year ended September 30, 2023; this is an annual report, not a standalone 2023 fourth-quarter filing. Financial statements are audited under U.S. GAAP. The company is a Cayman Islands holding company whose pharmaceutical operations are conducted through subsidiaries in China.
Business context and financial performance
The company manufactures and sells traditional Chinese medicine derivative (TCMD) products and distributes third-party pharmaceutical and medical products in China. It manufactured 13 product varieties and sold products in 30 provinces. Its largest product, Guben Yanling Pill, represented 36.4% of revenue.
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | $32.31 million | $40.14 million |
| Gross profit / margin | $10.32 million / 31.9% | $21.89 million / 54.5% |
| Operating loss | $3.53 million | $7.44 million |
| Net loss | $6.16 million | $8.74 million |
| Net cash from (used in) operations | $1.12 million | $(1.31) million |
| Cash at year-end | $5.29 million | $5.71 million |
Revenue from self-manufactured TCMD products was $18.57 million, down 22.6%; third-party product revenue was $13.74 million, down 15.0%. No individual customer exceeded 10% of revenue, but the top 10 customers contributed 27.2%.
Liquidity, debt and commitments
- At September 30, 2023, current assets were $36.81 million and current liabilities were $13.75 million; reported working capital was $23.1 million.
- Cash was $5.29 million and short-term investments were $13.22 million. Accounts receivable, net, was $10.67 million; the company reported that approximately 58.6% ($6.5 million) was subsequently collected.
- Short-term bank loans totaled $5.48 million, compared with $3.94 million a year earlier. The company also reported $0.54 million due to related parties, primarily non-interest-bearing, on-demand advances.
- Contractual obligations totaled $20.81 million, including $13.13 million of remaining construction spending, $2.19 million for a property purchase, and $5.48 million of debt due within one year.
- Management said available cash, operating cash flows, redeemable short-term investments and potential borrowing would be sufficient for working capital needs over the next 12 months. This is management’s assessment, not a guarantee.
Material changes and management commentary
- Revenue fell 19.5%, while cost of revenue rose 20.5%. Gross margin contracted 22.6 percentage points to 31.9%.
- TCMD unit sales increased 55.1%, but average selling price fell 50.0% to $1.11 per unit after the company cut prices to pursue volume and market share. TCMD gross margin fell to 27.8% from 65.9%.
- Management attributed pressure on TCMD costs to raw-material supply constraints and higher input prices; it reported traditional Chinese medicine raw-material prices rose about 14% year over year. RMB depreciation also reduced reported revenue and gross profit, with management estimating a 7.6% negative impact.
- Selling expenses fell 64.5%, mainly because advertising expense declined to $4.65 million from $17.53 million after a prior television advertising arrangement ended. R&D expense fell 36.4% to $4.86 million as earlier new-product development projects reached later stages.
- Operating cash flow turned positive despite the net loss, supported in part by a $4.72 million reduction in accounts receivable and higher accounts payable; inventory increased $1.18 million.
- Income-tax expense was $2.31 million despite a pretax loss. The filing cites a $1.63 million deferred-tax valuation allowance related to the expected realization of tax assets. Universe Trade lost its high-and-new-technology-enterprise tax status and is expected to move to the 25% standard tax rate from January 2024; Jiangxi Universe’s 15% status runs through November 2025.
Outlook, risks and unusual items
- No quantified revenue, earnings or margin guidance is provided. Management expects to pursue brand development, expand distribution, increase manufacturing capacity and develop new products; it also expects some operating costs and capital spending to rise.
- A construction project for four factories and an office building has an estimated remaining spend of $13.1 million. The filing gives differing timing descriptions: one section estimates completion in December 2025, while a note says factory buildings are expected by December 2024 and the office building by December 2025. The timing should be clarified.
- The company has a $3.43 million prepayment toward a proposed acquisition of 51% of Yunnan Faxi; completion and the remaining payment were expected by the end of 2024. Execution and funding risks remain.
- Material weaknesses in financial reporting controls remained unremediated at September 30, 2023, arising from insufficient accounting staff and U.S. GAAP/SEC reporting expertise. Management’s disclosure controls were deemed ineffective. The auditor issued an unqualified opinion on the financial statements but did not attest to internal controls.
- Other key risks include raw-material and supplier concentration (one supplier represented 29.6% of purchases), pharmaceutical regulation and product liability, competition and pricing pressure, foreign-exchange and cash-transfer restrictions, PRC regulatory uncertainty, and reliance on a controlled-company structure. The company says it does not carry product-liability or business-interruption insurance.
- Management reported no material litigation and no cybersecurity review or inquiry as of the report date. The company had not paid dividends and did not expect to do so in the foreseeable future. A subsequent event was a November 2023 two-year RMB15 million bank loan, secured by certain land and property.
Investor verification priorities
- Reconcile the share count: the cover page reports 3,645,974 ordinary shares at September 30, 2023, while the audited balance sheet reports 3,625,000 shares; confirm the correct outstanding amount and date.
- Clarify the factory and office construction schedule, remaining cash requirements, and whether the project remains on budget.
- Track collections of the remaining September 2023 receivables and confirm the quality of operating cash flow, including working-capital movements.
- Assess whether price reductions can sustain TCMD volume and restore product margins amid higher raw-material costs and currency effects.
- Monitor progress in remediating the material weakness and verify that future filings and financial statements are supported by adequate U.S. GAAP reporting resources.
- Confirm the status, approvals, financing and expected completion of the Yunnan Faxi acquisition, and review related-party property and borrowing arrangements.
- Verify refinancing or repayment of short-term bank loans and the impact of Universe Trade’s loss of its preferential tax status.